ReP USP - Resultado da busca

Artigo de periodico
Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder (2019)
Dos Santos, Rafael Guimarães dos ; Osório, Flávia de Lima ; Martin-Santos, Rocio ; Zuardi, Antônio Waldo ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza
Fonte: CNS Drugs. Unidade: FMRP
Assuntos: TRANSTORNOS DA ANSIEDADE, ANSIEDADE SOCIAL, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOS SANTOS, Rafael Guimarães dos et al. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder. CNS Drugs, v. 33, n. 10, p. 1031-1038, 2019Tradução . . Disponível em: https://doi.org/10.1007/s40263-019-00669-5. Acesso em: 08 jul. 2024.
APA
Dos Santos, R. G. dos, Osório, F. de L., Martin-Santos, R., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. de S. (2019). Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder. CNS Drugs, 33( 10), 1031-1038. doi:10.1007/s40263-019-00669-5
NLM
Dos Santos RG dos, Osório F de L, Martin-Santos R, Zuardi AW, Hallak JEC, Crippa JA de S. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder [Internet]. CNS Drugs. 2019 ; 33( 10): 1031-1038.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-019-00669-5
Vancouver
Dos Santos RG dos, Osório F de L, Martin-Santos R, Zuardi AW, Hallak JEC, Crippa JA de S. Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder [Internet]. CNS Drugs. 2019 ; 33( 10): 1031-1038.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-019-00669-5
Artigo de periodico
Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system (2018)
Schonhofen, Patrícia; Bristot, Ivi Juliana; Crippa, José Alexandre de Souza; Hallak, Jaime Eduardo Cecílio; Zuardi, Antônio Waldo; Parsons, Richard B.; Klamt, Fábio
Fonte: CNS Drugs. Unidade: FMRP
Assuntos: CANNABIS, TERAPÊUTICA MÉDICA, SISTEMA NERVOSO CENTRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHONHOFEN, Patrícia et al. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs, v. 32, n. 8, p. 697-712, 2018Tradução . . Disponível em: https://doi.org/10.1007/s40263-018-0550-4. Acesso em: 08 jul. 2024.
APA
Schonhofen, P., Bristot, I. J., Crippa, J. A. de S., Hallak, J. E. C., Zuardi, A. W., Parsons, R. B., & Klamt, F. (2018). Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs, 32( 8), 697-712. doi:10.1007/s40263-018-0550-4
NLM
Schonhofen P, Bristot IJ, Crippa JA de S, Hallak JEC, Zuardi AW, Parsons RB, Klamt F. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system [Internet]. CNS Drugs. 2018 ; 32( 8): 697-712.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-018-0550-4
Vancouver
Schonhofen P, Bristot IJ, Crippa JA de S, Hallak JEC, Zuardi AW, Parsons RB, Klamt F. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system [Internet]. CNS Drugs. 2018 ; 32( 8): 697-712.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-018-0550-4
Artigo de periodico
Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review (2013)
Fragoso, Yara D.; Adoni, Tarso; Alves-Leon, Soniza V.; Azambuja Jr, Nério D.; Barreira, Amilton Antunes; Brooks, Joseph B. B.; Carneiro, Denise S. D.; Carvalho, Margarete J.; Claudino, Rinaldo; Comini-Frota, Elizabeth R.; Domingues, Renan B.; Finkelzstejn, Alessandro; Gama, Paulo D.; Giacomo, Maria C. B.; Gomes, Sidney; Goncalves, Marcus V. M.; Grzesiuk, Anderson K.; Kaimen-Maciel, Damacio R.; Mendes, Maria F.; Morales, Nivea M. O.; Morales, Rogério R.; Muniz, Andre; Papais-Alvarenga, Regina M.; Parolin, Monica K. F.; Ribeiro, Sonia B. F.; Ruocco, Heloisa H.; Siquineli, Fabio; Tosta, Elza D.
Fonte: CNS Drugs. Unidade: FMRP
Assuntos: TEMPO, EXPOSIÇÃO MATERNA, ESCLEROSE MÚLTIPLA, GRAVIDEZ, FETO, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRAGOSO, Yara D. et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs, v. 27, n. 11, p. 955-961, 2013Tradução . . Disponível em: https://doi.org/10.1007/s40263-013-0113-7. Acesso em: 08 jul. 2024.
APA
Fragoso, Y. D., Adoni, T., Alves-Leon, S. V., Azambuja Jr, N. D., Barreira, A. A., Brooks, J. B. B., et al. (2013). Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs, 27( 11), 955-961. doi:10.1007/s40263-013-0113-7
NLM
Fragoso YD, Adoni T, Alves-Leon SV, Azambuja Jr ND, Barreira AA, Brooks JBB, Carneiro DSD, Carvalho MJ, Claudino R, Comini-Frota ER, Domingues RB, Finkelzstejn A, Gama PD, Giacomo MCB, Gomes S, Goncalves MVM, Grzesiuk AK, Kaimen-Maciel DR, Mendes MF, Morales NMO, Morales RR, Muniz A, Papais-Alvarenga RM, Parolin MKF, Ribeiro SBF, Ruocco HH, Siquineli F, Tosta ED. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review [Internet]. CNS Drugs. 2013 ; 27( 11): 955-961.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-013-0113-7
Vancouver
Fragoso YD, Adoni T, Alves-Leon SV, Azambuja Jr ND, Barreira AA, Brooks JBB, Carneiro DSD, Carvalho MJ, Claudino R, Comini-Frota ER, Domingues RB, Finkelzstejn A, Gama PD, Giacomo MCB, Gomes S, Goncalves MVM, Grzesiuk AK, Kaimen-Maciel DR, Mendes MF, Morales NMO, Morales RR, Muniz A, Papais-Alvarenga RM, Parolin MKF, Ribeiro SBF, Ruocco HH, Siquineli F, Tosta ED. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review [Internet]. CNS Drugs. 2013 ; 27( 11): 955-961.[citado 2024 jul. 08 ] Available from: https://doi.org/10.1007/s40263-013-0113-7
Artigo de periodico
Evaluation of serum levels of chemokines during interferon-'beta' treatment in multiple sclerosis patients: A 1-year, observational cohort study (2011)
Comini-Frota, Elizabeth R.; Teixeira, Antonio L.; Angelo, Janaína P. A.; Andrade, Marcus V.; Brum, Doralina G.; Kaimen-Maciel, Damacio R.; Foss, Norma Tiraboschi; Donadi, Eduardo Antonio
Fonte: CNS Drugs. Unidade: FMRP
Assuntos: ESCLEROSE MÚLTIPLA (ESTUDO), CITOCINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COMINI-FROTA, Elizabeth R. et al. Evaluation of serum levels of chemokines during interferon-'beta' treatment in multiple sclerosis patients: A 1-year, observational cohort study. CNS Drugs, v. 25, n. 11, p. 913-931, 2011Tradução . . Disponível em: https://doi.org/10.2165/11595900-000000000-00000. Acesso em: 08 jul. 2024.
APA
Comini-Frota, E. R., Teixeira, A. L., Angelo, J. P. A., Andrade, M. V., Brum, D. G., Kaimen-Maciel, D. R., et al. (2011). Evaluation of serum levels of chemokines during interferon-'beta' treatment in multiple sclerosis patients: A 1-year, observational cohort study. CNS Drugs, 25( 11), 913-931. doi:10.2165/11595900-000000000-00000
NLM
Comini-Frota ER, Teixeira AL, Angelo JPA, Andrade MV, Brum DG, Kaimen-Maciel DR, Foss NT, Donadi EA. Evaluation of serum levels of chemokines during interferon-'beta' treatment in multiple sclerosis patients: A 1-year, observational cohort study [Internet]. CNS Drugs. 2011 ; 25( 11): 913-931.[citado 2024 jul. 08 ] Available from: https://doi.org/10.2165/11595900-000000000-00000
Vancouver
Comini-Frota ER, Teixeira AL, Angelo JPA, Andrade MV, Brum DG, Kaimen-Maciel DR, Foss NT, Donadi EA. Evaluation of serum levels of chemokines during interferon-'beta' treatment in multiple sclerosis patients: A 1-year, observational cohort study [Internet]. CNS Drugs. 2011 ; 25( 11): 913-931.[citado 2024 jul. 08 ] Available from: https://doi.org/10.2165/11595900-000000000-00000

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Indexado em

Afiliação dos autores externos não normalizada